Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Ketamine shows promise for rapid relief of suicidal ideation

NCT ID NCT02299440

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether ketamine, given as two infusions, can quickly reduce suicidal thoughts in 156 hospitalized patients at high risk for suicide. The main goal was to see if suicidal ideas resolved within 24 hours after the second dose. The approach aims to provide fast, short-term relief during a crisis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

156 people

The number who actually took part.

Started

Apr 2015

Finished

Nov 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * French speaking patients freely hospitalized for prevention of suicide and who have a medium or high suicide risk score according to a MINI structured interview * The patient is able to understand how the study is carried out and the tests performed * The patient is deemed capable of giving his/her informed consent * The patient has been correctly informed * The patient must have given his/her informed and signed consent. * The patient must be insured or beneficiary of a health insurance plan. * Presence of suicidal ideation according to the SSI score (score \> 3) * Negative pregnancy test for women of childbearing age Exclusion Criteria: * The patient is participating in another interventional study * Within the past three months, the patient has participated in another interventional study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection * The patient is an adult under guardianship * The patient refuses to sign the consent * The patient is not able to understand the informed consent * Pregnancy or breastfeeding * History of schizophrenia or other psychotic disorders * Presence of psychotic symptoms at initial interview * Schizoid or schizotypic personality disorder * Positive urine screening for illicit substances, excluding cannabis * Substance dependence in the preceding month (excluding nicotine or caffeine) * Concomitant treatment with electroconvulsive therapy * Unstable somatic pathology * Clinically significant anomalies found during clinical examination, biological test or ECG * Non-stabilized hypertension or hypertension \> 180/100 * Known or suspected contra-indication for ketamine (includes interactions): hypersensitivity to ketamine, hypertension, class IV cardiac insufficiency, history of stroke, hepatic or cutaneous porphyria, history of intracranial hypertension

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Suicidal ideation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Suicidal Ideation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • APHP - Hôpital Lariboisière

    Paris, 75010, France

  • CHRU de Lille - Hôpital Michel Fontan

    Lille, 59037, France

  • CHRU de Montpellier - Hôpital Lapeyronie

    Montpellier, 34295, France

  • CHRU de Nîmes - Hôpital Universitaire Carémeau

    Nîmes, 30029, France

  • CHRU de Tours - Clinique Psychiatrique Universitaire

    Saint-Cyr-sur-Loire, 37540, France

  • CHU de Clermont Ferrand - Hôpital Gabriel-Montpied

    Clermont-Ferrand, 63003, France

  • CMME Centre Hospitalier Sainte Anne

    Paris, 75674, France

  • Centre Hospitalier Sainte-Anne

    Paris, 75674, France

  • Clinique Les Sophoras

    Nîmes, 30000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.